Application of the p53 signature in the same 5 cohorts of neadjuvant treated breast cancer patients revealed a robust relationship between the p53 signature and patient response (Figure 5D & Supplementary Figure 7, Supplementary Table 8; 5 cohorts; total n = 1066; AUC > 0.5). Here, TP53 is linked to breast carcinoma.